Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05776342
Recruiting Observational

Prognostic and Predictive Markers of Treatment Response in Patients With PAC.

NCT05776342 · tracked via the Priya Life Science France tracker
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Observational
Started
2003-01-01
Last updated
2025-03-25

Condition(s) studied

Pancreatic Adenocarcinoma

Study summary

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient with histologically confirmed pancreatic adenocarcinoma. * Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery * Diagnosis between January 1, 2003, and December 31, 2030. * First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials. * Age ≥ 18 years. * Written informed consent Exclusion Criteria: * Patient under guardianship, curatorship, or judicial protection. * Pregnant or breastfeeding women. * Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator. * Refusal to participate in the study

Primary outcome measure(s)

  • Overall Survival (OS) rate — Up to 7 years from the date of initial cancer diagnosis (or until death if it occurs before 17 years)
    Defined as the time interval between the start date of treatment (surgery, first cycle of L1 chemotherapy, or first radiotherapy session) and the date of death regardless of the cause. Living or lost to follow-up patients will be censored at the date of the last news

Trial sites (15)

FacilityCityRegionStatus
CHU Jean Minjoz Besançon France Recruiting
Hôpital Beaujon Clichy France Recruiting
CHU - Henri Mondor Créteil France Not Yet Recruiting
CHU Lille Lille France Recruiting
Centre Léon Bérard Lyon France Not Yet Recruiting
HRU Nancy Site Brabois Nancy France Recruiting
Hôpital Georges Pompidou Paris France Recruiting
Hôpital Saint Antoine Paris France Recruiting
Institut Mutualiste Montsouris Paris France Not Yet Recruiting
CHU Poitiers Poitiers France Not Yet Recruiting
CHU Reims Reims France Not Yet Recruiting
CHU Pontchaillou Rennes France Not Yet Recruiting
Institut Curie Saint-Cloud France Not Yet Recruiting
IHU - Institut de chirurgie guidée par l'imagerie Strasbourg France Not Yet Recruiting
Hôpital Paul Brousse Villejuif France Recruiting

More GERCOR - Multidisciplinary Oncology Cooperative Group trials in France

QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. Active, not recruiting
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC Recruiting
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. Active, not recruiting
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. Active, not recruiting
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. Active, not recruiting

Other trials for the same condition

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Recruiting
Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas Starting soon
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers Recruiting
Biological and Clinical Database for Pancreatic Adenocarcinoma Active, not recruiting
Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05776342 on ClinicalTrials.gov ↗ ← All trials in France